CBS Tau Phosphorylation Pathways

Migration, Crosslink

📖

CBS Tau Phosphorylation Pathways

active

wiki page Created: 2026-04-02T07:19:56 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-cbs-tau-phosphorylation

📖 Wiki Page

mechanism1501 wordssynced 2026-04-02

CBS Tau Phosphorylation Pathways

Overview

Corticobasal Syndrome (CBS) is a progressive neurodegenerative disorder characterized by asymmetric cortical atrophy, basal ganglia degeneration, and prominent movement abnormalities. A defining pathological feature of CBS is the abnormal accumulation of four-repeat (4R) [tau protein](/proteins/tau) in [neurons](/entities/neurons) and glia. This mechanism page focuses on the dysregulation of tau phosphorylation in CBS, examining the key kinases and phosphatases involved, how 4R tau isoform imbalance affects phosphorylation patterns, and how this differs from Alzheimer's disease tau pathology.

Tau Phosphorylation Biology

Normal Tau Function

Tau is a microtubule-associated protein primarily expressed in neurons where it stabilizes microtubules in axons and modulates axonal transport. Under normal conditions, tau phosphorylation is tightly regulated, with approximately 2-3 moles of phosphate per mole of tau. This phosphorylation state allows dynamic regulation of microtubule binding affinity in response to cellular signaling needs.

Phosphorylation Sites

Tau has over 85 potential phosphorylation sites, primarily on serine and threonine residues, with a smaller number on tyrosine residues. These sites are clustered in:

Proline-rich domain (PRD): Ser199, Ser202, Thr205, Thr212, Ser214, Ser235
Microtubule-binding repeats (R1-R4): Ser262, Ser356, Ser396, Ser404, Ser422

...

CBS Tau Phosphorylation Pathways

Overview

Corticobasal Syndrome (CBS) is a progressive neurodegenerative disorder characterized by asymmetric cortical atrophy, basal ganglia degeneration, and prominent movement abnormalities. A defining pathological feature of CBS is the abnormal accumulation of four-repeat (4R) [tau protein](/proteins/tau) in [neurons](/entities/neurons) and glia. This mechanism page focuses on the dysregulation of tau phosphorylation in CBS, examining the key kinases and phosphatases involved, how 4R tau isoform imbalance affects phosphorylation patterns, and how this differs from Alzheimer's disease tau pathology.

Tau Phosphorylation Biology

Normal Tau Function

Tau is a microtubule-associated protein primarily expressed in neurons where it stabilizes microtubules in axons and modulates axonal transport. Under normal conditions, tau phosphorylation is tightly regulated, with approximately 2-3 moles of phosphate per mole of tau. This phosphorylation state allows dynamic regulation of microtubule binding affinity in response to cellular signaling needs.

Phosphorylation Sites

Tau has over 85 potential phosphorylation sites, primarily on serine and threonine residues, with a smaller number on tyrosine residues. These sites are clustered in:

Proline-rich domain (PRD): Ser199, Ser202, Thr205, Thr212, Ser214, Ser235
Microtubule-binding repeats (R1-R4): Ser262, Ser356, Ser396, Ser404, Ser422

The phosphorylation state at these sites determines tau's functional properties, including microtubule binding affinity, aggregation propensity, and subcellular localization.

Key Kinases Implicated in CBS

Glycogen Synthase Kinase-3β (GSK3β)

GSK3β is the primary kinase implicated in tau hyperphosphorylation in CBS and other tauopathies.

Activity: Constitutively active serine/threonine kinase
Key phosphorylation sites: Ser199, Ser202, Thr205, Ser396, Ser404
Regulation: Inhibited by Akt-mediated phosphorylation at Ser9
Role in CBS: GSK3β activity is elevated in CBS brain tissue, and its activation correlates with the density of tau-positive inclusions

GSK3β preferentially phosphorylates tau at sites flanking the microtubule-binding repeats, leading to reduced microtubule binding and increased aggregation propensity.

Cyclin-Dependent Kinase 5 (CDK5)

[CDK5](/proteins/cdk5) is a neuron-specific kinase critical for neuronal development and function.

Activation: Requires binding to regulatory subunits p35 or p39
Key phosphorylation sites: Ser199, Ser202, Thr205, Ser235
Dysregulation in CBS: Calpain-mediated cleavage of p35 to p25 leads to prolonged CDK5 activation
Role in CBS: CDK5 hyperactivity contributes to pathological tau phosphorylation in CBS, particularly in neurons with 4R tau inclusions

The p25/CDK5 complex shows increased activity in CBS brains, making it a therapeutic target of interest.

Microtubule Affinity-Regulating Kinase (MARK)

The MARK family (MARK1-4) regulates microtubule dynamics through tau phosphorylation.

Key phosphorylation sites: Ser262, Ser356 (within microtubule-binding repeats)
Role in CBS: Phosphorylation at these sites dramatically reduces tau's microtubule binding affinity
Specificity: MARK preferentially phosphorylates 4R tau isoforms due to structural differences in the repeat domain

MARK-mediated phosphorylation at Ser262 is considered an early event in tau pathology, as it displaces tau from microtubules, making it available for aggregation.

Protein Kinase A (PKA)

PKA is a cAMP-dependent kinase that modulates tau phosphorylation in response to neurotransmitter signaling.

Key phosphorylation sites: Ser396, Ser404, Ser214
Role in CBS: PKA activity is dysregulated in CBS, potentially due to altered cAMP signaling
Interaction with other kinases: PKA can prime tau for subsequent phosphorylation by GSK3β

Calcium/Calmodulin-Dependent Protein Kinase II (CaMKII)

CaMKII is abundant in neurons and activated by calcium influx.

Key phosphorylation sites: Ser416, Thr231
Role in CBS: Excitotoxicity and calcium dysregulation in CBS may lead to CaMKII activation
Pathological significance: CaMKII-mediated tau phosphorylation may contribute to synaptic dysfunction

Mermaid diagram (expand to render)

Key Phosphatases

Protein Phosphatase 2A (PP2A)

PP2A is the major phosphatase responsible for tau dephosphorylation.

Activity: Accounts for approximately 70% of tau dephosphorylation activity in the brain
Key dephosphorylation sites: All major phospho-sites including Ser199, Ser202, Thr205, Ser396, Ser404
Regulation: PP2A activity is regulated by methylation, phosphorylation, and inhibitor proteins
Role in CBS: PP2A activity is reduced in CBS brains, contributing to net tau hyperphosphorylation

The downregulation of PP2A in CBS may result from:

Reduced expression of PP2A subunits
Increased methylation of PP2A
Accumulation of endogenous PP2A inhibitors

Protein Phosphatase 1 (PP1)

PP1 also contributes to tau dephosphorylation but has a more limited role.

Key dephosphorylation sites: Primarily Ser396 and Ser404
Role in CBS: PP1 activity is also reduced in CBS, though less dramatically than PP2A
Therapeutic potential: PP1 activators have been proposed as therapeutic agents

Mermaid diagram (expand to render)

4R Tau Isoform Imbalance and Phosphorylation Patterns

The 4R Tau Predominance

Unlike Alzheimer's disease, where both 3R and 4R tau are present in neurofibrillary tangles, CBS is characterized by a predominance of 4R tau isoforms (approximately 75% 4R, 25% 3R).

How 4R Tau Affects Phosphorylation

The 4R tau isoform has distinct phosphorylation characteristics:

Additional microtubule-binding repeat (R2): Contains additional phosphorylation sites that are absent in 3R tau

Higher basal phosphorylation: 4R tau has inherently higher phosphorylation at some sites due to structural accessibility

Distinct phosphorylation patterns: Cryo-EM studies show different phosphorylation patterns in 4R tau filaments compared to 3R/4R mixed filaments

The MAPT H1 haplotype, which is the major genetic risk factor for CBS, promotes exon 10 inclusion, leading to increased 4R tau expression.

Phosphorylation Site Specificity in 4R Tau

| Site | 3R Tau | 4R Tau | CBS Relevance |
|------|--------|--------|---------------|
| Ser202 | ✓ | ✓ | Early marker |
| Thr205 | ✓ | ✓ | Pathological |
| Ser262 | — | ✓ | 4R-specific |
| Ser356 | — | ✓ | 4R-specific |
| Ser396 | ✓ | ✓ | Aggregation |
| Ser404 | ✓ | ✓ | Late-stage |

Comparison with Alzheimer's Disease Tau Phosphorylation

Key Differences

| Feature | Alzheimer's Disease | Corticobasal Syndrome |
|---------|---------------------|----------------------|
| Tau isoform | 3R + 4R (mixed) | Predominantly 4R |
| Primary kinases | GSK3β, CDK5 | GSK3β, CDK5, MARK |
| Phosphatase deficit | Severe PP2A reduction | Moderate PP2A reduction |
| Phosphorylation pattern | Broad, many sites | Specific sites predominant |
| Filament type | Paired helical filaments (PHFs) | Straight filaments, 4R-specific |
| Cell types affected | Pyramidal neurons | Neurons + astrocytes |
| Regional pattern | Braak staging | Asymmetric cortical |

Cryo-EM Structural Evidence

Cryo-EM studies have revealed distinct tau filament structures in CBS compared to AD:

CBS filaments: Composed of 4R tau with a distinct C-shaped fold
AD filaments: Mixed 3R/4R tau with paired helical filament structure
CBD-specific structures: "Astrogliopathic" tau with distinct protofilament arrangements

These structural differences explain the distinct phosphorylation patterns and clinical presentations.

Mermaid diagram (expand to render)

Kinase Inhibitor Therapeutic Approaches

GSK3β Inhibitors

Clinical status: Preclinical to Phase 1

Lithium: First-generation GSK3β inhibitor, shown to reduce tau phosphorylation in models
Tideglusib: Small-molecule GSK3β inhibitor, completed Phase 2 trials for AD and PSP
Challenges: Toxicity due to broad kinase inhibition, limited brain penetration

CDK5 Inhibitors

Clinical status: Preclinical

Roscovitine: CDK5 inhibitor shown to reduce tau phosphorylation
Challenges: CDK5 is essential for neuronal function, systemic inhibition may be toxic

MARK Inhibitors

Clinical status: Preclinical

Target: Specifically inhibit MARK-mediated Ser262 phosphorylation
Advantage: More selective targeting possible
Challenge: [Blood-brain barrier](/entities/blood-brain-barrier) penetration

Multi-Kinase Inhibitors

Given that multiple kinases contribute to tau hyperphosphorylation, combination approaches are being explored:

Rationale: Simultaneous inhibition of GSK3β, CDK5, and other kinases
Challenge: Balancing efficacy with toxicity

Phosphatase-Activating Strategies

An alternative approach involves activating [PP2A](/entities/pp2a):

Calyculin A: PP2A activator, shown to reduce tau phosphorylation
Challenges: PP2A activation may have off-target effects

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Arendt et al., Tau and neurodegeneration (2016) (2016)](https://doi.org/10.1007/s00401-016-1548-y)

[Hutton et al., FTDP-17 tau mutations (1998) (1998)](https://doi.org/10.1038/25151)

[Fitzpatrick et al., Cryo-EM structures of tau filaments from Alzheimer's disease (2017) (2017)](https://doi.org/10.1038/nature23002)

[Furman et al., Tau pathology in corticobasal syndrome (2015) (2015)](https://doi.org/10.1007/s00401-015-1439-9)

[Kouri et al., Novel tau mutations in corticobasal degeneration (2014) (2014)](https://doi.org/10.1007/s00401-014-1269-z)

[Shi et al., MARK4 promotes tau aggregation and phosphorylates Ser262 (2016) (2016)](https://doi.org/10.1016/j.jbc.M116.720980)

[Wang et al., PP2A deficit in tauopathy (2018) (2018)](https://doi.org/10.1038/s41467-018-04493-1)

[Matsumoto et al., CDK5 dysregulation in neurodegeneration (2005) (2005)](https://doi.org/10.1016/j.tics.2005.09.005)

[Ferrer et al., Protein phosphatases in tauopathies (2002) (2002)](https://doi.org/10.1007/s00401-002-0528-5)

[Zhang et al., 4R tau-specific phosphorylation patterns (2020) (2020)](https://doi.org/10.1007/s00401-020-02138-6)

📖 View canonical wiki page →

Related Entities

mechanisms-cbs-tau-phosphorylation

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-cbs-tau-phosphorylation
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-b59e957d7bc7
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-cbs-tau-phosphorylation'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

39

Outgoing

48

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

CBS Tau Phosphorylation Pathways

CBS Tau Phosphorylation Pathways

Overview

Tau Phosphorylation Biology

Normal Tau Function

Phosphorylation Sites

CBS Tau Phosphorylation Pathways

Overview

Tau Phosphorylation Biology

Normal Tau Function

Phosphorylation Sites

Key Kinases Implicated in CBS

Glycogen Synthase Kinase-3β (GSK3β)

Cyclin-Dependent Kinase 5 (CDK5)

Microtubule Affinity-Regulating Kinase (MARK)

Protein Kinase A (PKA)

Calcium/Calmodulin-Dependent Protein Kinase II (CaMKII)

Key Phosphatases

Protein Phosphatase 2A (PP2A)

Protein Phosphatase 1 (PP1)

4R Tau Isoform Imbalance and Phosphorylation Patterns

The 4R Tau Predominance

How 4R Tau Affects Phosphorylation

Phosphorylation Site Specificity in 4R Tau

Comparison with Alzheimer's Disease Tau Phosphorylation

Key Differences

Cryo-EM Structural Evidence

Kinase Inhibitor Therapeutic Approaches

GSK3β Inhibitors

CDK5 Inhibitors

MARK Inhibitors

Multi-Kinase Inhibitors

Phosphatase-Activating Strategies

See Also

External Links

References

💬 Discussion